Institut Rosell Expands Into ChileInstitut Rosell Expands Into Chile
December 18, 2007
MONTREALInstitut Rosell-Lallemand announced a probiotic preparation based on its proprietary strain, Lactobacillus plantarum 299v, which has been studied for the treatment of irritable bowel syndrome (IBS), was launched by Merck Chile as Bion Transit. More launches are expected in the South American market into 2008.
The licensing agreement signed with Merck Chile for Lp299v probiotic follows on the heels of the successful launch of Bion Transit by Merck Médication Familiale in France two years ago, said Sylvie Morin, sales and marketing director for the Americas, Institut Rosell (Lallemand.com). Bion Transit has become the leading probiotic targeting bloating and gas reduction in the French market, and we are confident that our Lp299v probiotic is a good candidate to penetrate the South American market as it constitutes a natural and clinically proven solution in supporting IBS sufferers.
You May Also Like
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023
More bioavailable hyaluronic acid complex for today’s beauty-from-within consumer – snapshotSep 18, 2023
Herbalife launches fitness campaign as it strives to regain sales momentumSep 20, 2023